Monopar Therapeutics Q2 EPS $(0.10) Misses $(0.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics (NASDAQ:MNPR) reported a Q2 EPS of $(0.10), missing the analyst consensus estimate of $(0.09) by 11.11%. This represents a 37.5% improvement over the $(0.16) per share loss from the same period last year.
August 09, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Monopar Therapeutics reported a Q2 EPS of $(0.10), missing the analyst estimate of $(0.09) by 11.11%. Despite the miss, the loss is a 37.5% improvement from the same period last year.
The EPS miss is likely to have a negative short-term impact on MNPR's stock price as it failed to meet analyst expectations. However, the year-over-year improvement in losses may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100